Claim Missing Document
Check
Articles

Found 3 Documents
Search

Analysis Difference between INR and D-dimer against Mortality COVID-19 patients Herda Asyari, Claudia; Noor Chozin, Iin; Rakhma, Sastia
Indonesian Health Journal Vol. 2 No. 4 (2023): Indonesian Health Journal
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58344/ihj.v2i4.281

Abstract

As of July 2022, COVID-19 has infected 565 million people, with 6.3 million deaths worldwide. The relationship between laboratory parameters with time to death and comorbidities has not been widely studied. This study determines the difference between INR and D-dimer on the mortality of COVID-19 patients at Dr. Hospitals. In a retrospective cohort study conducted in April 2020 - September 2021, 229 COVID-19 subjects were diagnosed with swab PCR. Data analysis included time to death from hospital admission divided into <7 days and >7 days, laboratory data, comorbidity data, and no comorbidity. Data were tested using Chi-Square for categorical data, Mann-Whitney, and Kruskall Wallis for numerical data. Overall, INR levels were significantly higher in subjects with comorbidities compared to those without (p<0.05). This was based on the time to death of subjects <7 days without comorbidities. In addition, the change from hypercoagulation to hyperfibrinolysis due to excessive coagulant consumption factors, resulting in increased PT and INR in severe COVID-19 conditions. Overall, it was found that INR levels were significantly higher in subjects with comorbidities compared to subjects without comorbidities, as well as D-dimer in subjects with a time of death >7 days without comorbidities was significantly higher compared to other subject groups.
Analysis Difference between INR and D-dimer against Mortality COVID-19 patients Herda Asyari, Claudia; Noor Chozin, Iin; Rakhma, Sastia
Indonesian Health Journal Vol. 2 No. 4 (2023): Indonesian Health Journal
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58344/ihj.v2i4.281

Abstract

As of July 2022, COVID-19 has infected 565 million people, with 6.3 million deaths worldwide. The relationship between laboratory parameters with time to death and comorbidities has not been widely studied. This study determines the difference between INR and D-dimer on the mortality of COVID-19 patients at Dr. Hospitals. In a retrospective cohort study conducted in April 2020 - September 2021, 229 COVID-19 subjects were diagnosed with swab PCR. Data analysis included time to death from hospital admission divided into <7 days and >7 days, laboratory data, comorbidity data, and no comorbidity. Data were tested using Chi-Square for categorical data, Mann-Whitney, and Kruskall Wallis for numerical data. Overall, INR levels were significantly higher in subjects with comorbidities compared to those without (p<0.05). This was based on the time to death of subjects <7 days without comorbidities. In addition, the change from hypercoagulation to hyperfibrinolysis due to excessive coagulant consumption factors, resulting in increased PT and INR in severe COVID-19 conditions. Overall, it was found that INR levels were significantly higher in subjects with comorbidities compared to subjects without comorbidities, as well as D-dimer in subjects with a time of death >7 days without comorbidities was significantly higher compared to other subject groups.
Well Differentiated B3 Thymoma complicated with Vena Cava Superior Syndrome undergo Debulking and Chemotherapy Semara Putra, Wayan Wahyu; Noor Chozin, Iin; Wantry, Kenty; Isharanto, Artono; Erawati, Rachma Dini
Malang Respiratory Journal Vol. 2 No. 01 (2020): Shape the Curves
Publisher : Universitaas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mrj.2020.002.01.4

Abstract

Background: Thymoma is a rare neoplasm. This incident is comparable to 390 new cases reported per year. Genetic factors are believed to be one of the factors of B3 thymoma and thymus carcinoma. Multimodality of thymoma therapy (surgery, radiation and chemotherapy) gives better results.Case Report: Mr A, 29 years old, with initial diagnosis of stage IV thymoma (according to Masaoka) with SVKS then undergo debulking, followed by chemotherapy with a regimen of Cisplatin + Vincristin, Cyclophospamid, Doxorubicin, Prednison every 21 days as much as 6 times. Subjective responses indicated by reduced complaints of chest pain and loss of swelling of the right arm. Semisubjective response indicated by increase of body weight. Objective response is progressive, so can be continued with second line chemotherapy or radiotherapy.Conclusion: The prognosis of patient with well differentiated thymic carcinoma stadium iv (thymoma b3) complicated with vena cava superior syndrome was poor because of the objective response of the chemotherapy was progressive, and the relapse case was higher.